Biotech's Baby Companies Are Starving

This creates a vicious cycle. Early-stage companies need funding to generate the data that later-stage investors demand. Without seed capital, there's no preclinical work. Without preclinical work, there's no Phase 1 trial. Without a Phase 1 trial, nobody's writing a $300 million IPO check. The pipeline of future breakthroughs doesn't just slow down; it starts to dry up.

The Startup Graveyard Keeps Growing

We're already seeing the consequences. In 2025, at least 16 biotech startups fully shut down, with three more teetering on the edge. Some of them had real science and credible backers.

Lucy Therapeutics spent seven years developing treatments for Rett syndrome and Parkinson's disease. They had positive animal data. They simply couldn't raise enough to get into human trials. Doors closed in June 2025.

Arena BioWorks is perhaps the most dramatic cautionary tale. Launched with $500 million for AI-driven drug discovery, the company shut down entirely in November 2025, less than two years after its splashy debut. Changing macro conditions and weak follow-on funding did it in.

Abata Therapeutics, backed by respected firms like Third Rock Ventures, closed its doors in August 2025 after fundraising dried up for its cell therapy programs. Even a strong pedigree couldn't overcome the capital crunch.

Cell therapy took particularly heavy losses, with companies like Carisma Therapeutics, Oncternal, and Appia Bio all winding down despite partnerships with major pharma players.

Survival of the Most Creative

Startups that can't raise traditional venture rounds are getting scrappy. Think of it like a band that can't get a record deal: you start busking, selling merch, and sliding into DMs.

In biotech terms, that means three main survival strategies:

Non-dilutive grants (free money from governments and foundations that doesn't require giving up ownership) have become a lifeline. Sessions at BIO Convention 2026 are making them a centerpiece. The catch: you need enough runway to actually apply and wait, which not every startup has.

Venture debt offers another path, letting companies borrow money to fund R&D without selling more equity. It's increasingly paired with royalty financing, where startups pledge a slice of future drug revenue in exchange for cash today. Think of it like a musician selling a percentage of their streaming royalties to pay for studio time.

Pharma partnerships may be the most promising route. Large pharma companies topped the list of 2025 funding sources, and corporate venture arms from Sanofi and others are actively scouting early-stage assets. For startups, these deals come with built-in expertise, regulatory support, and the tantalizing possibility of an acquisition down the road.

Why You Should Care About Companies You've Never Heard Of

The biotech startups struggling to raise their first $10 million today are the same ones that might cure your disease in 2035. That's not hyperbole; it's how drug development works. Every blockbuster therapy was once a PowerPoint deck begging for seed funding.

Only about 32% of biotech deals in 2025 went to early-stage companies, down from over 40% during 2020 to 2022. The money hasn't disappeared from biotech; it's just migrating toward safer, later-stage bets. Investors who got burned during the 2021 bubble are now allergic to anything that smells like risk.

The problem is that all of biotech is risk. You can't de-risk drug development without actually doing drug development. And if nobody funds the earliest, riskiest experiments, the pipeline of future medicines gets thinner every year.

PitchBook anticipates a "disciplined recovery" continuing into 2026, which is analyst-speak for: don't expect the money spigot to turn back on anytime soon. Jonathan Norris at HSBC has predicted around 20 biotech IPOs in 2026, but those will almost exclusively be companies already deep into clinical trials.

For the scrappy startup with a brilliant idea and zero data? The message from Wall Street is clear: figure it out yourself. And that should worry all of us.

The Gene Therapy Company Betting Against Million-Dollar Price Tags

Gene therapies can cost millions per patient, and most never achieve commercial success. Ocugen's CEO thinks the industry is solving the wrong problem, and he's betting the company on manufacturing scale and affordable pricing over scientific novelty.